Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 213239, 9 pages
Review Article

A Network Meta-Analysis on Randomized Trials Focusing on the Preventive Effect of Statins on Contrast-Induced Nephropathy

1Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Corso della Repubblica 79, 04100 Latina, Italy
2Department of Cardiovascular Sciences, European Hospital, 00149 Rome, Italy
3Department of Radiology, Copenhagen University Hospital, 2100 Herlev, Denmark
4Division of Cardiology, Policlinico Casilino, 00169 Rome, Italy
5Division of Cardiology, University of Turin, 10126 Turin, Italy
6Department of Cardiovascular, Respiratory, Nephrologic and Geriatric Sciences, Sapienza University of Rome, 00185 Rome, Italy
7VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA 23298, USA
8Department of Angiocardioneurology, IRCCS Neuromed, 86077 Pozzilli, Italy

Received 16 April 2014; Accepted 6 August 2014; Published 7 September 2014

Academic Editor: Emmanuel A. Burdmann

Copyright © 2014 Mariangela Peruzzi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Contrast-induced nephropathy is a common complication of iodinated contrast administration. Statins may reduce the risk of contrast-induced nephropathy, but data remain inconclusive. We summarized the evidence based on statins for the prevention of contrast-induced nephropathy with a network meta-analysis. Randomized trials focusing on statins were searched and pooled with random-effect odds ratios. A total of 14 trials (6,160 patients) were included, focusing on atorvastatin (high/low dose), rosuvastatin (high dose), simvastatin (high/low dose), and placebo or no statin therapy before contrast administration. The risk of contrast-induced nephropathy was reduced by atorvastatin high dose and rosuvastatin high dose, with no difference between these two agents. Results for atorvastatin low dose and simvastatin (high/low dose) in comparison to placebo were inconclusive. Atorvastatin and rosuvastatin administered at high doses and before iodinated contrast administration have a consistent and beneficial preventive effect on contrast-induced nephropathy and may actually halve its incidence.